Skip to main content
Figure 5 | Molecular Cancer

Figure 5

From: The centrosome protein NEDD1 as a potential pharmacological target to induce cell cycle arrest

Figure 5

The Plk1 inhibitor BI2536 and siRNA against NEDD1 act synergistically to reduce cell viability. (A) Quantification of HCT116 p53+/+, p53-/-, or HeLa cells surviving after control RNA or NEDD1-siRNA transfection (0.5 nM) alone, or combined with BI2536 (10 nM in HCT116 cells, 5 nM in HeLa cells). The percentage of surviving cells is indicated as a percentage of the number of control cells (treated with control siRNA, without BI2536), quantified by trypan blue exclusion analysis after 48 h incubation. (B) Percentage of viable HeLa cells after 48 h treatment with variable concentrations of NEDD1-siRNA alone, or combined with 5 nM BI2536. (C) Percentage of viable HeLa cells after 48 h treatment with variable concentrations of BI2536 combined with 0.5 nM control or NEDD1-siRNA. (D, E) Percentage of viable HeLa cells after 48 h treatment with control or NEDD1-siRNA (0.5 nM) alone, or combined with paclitaxel (2.5 nM, D) or monastrol (60 μM, E). (F, G) Percentage of viable HeLa cells after 48 h treatment with variable concentrations of paclitaxel (F) or monastrol (G) combined with 0.5 nM control or NEDD1-siRNA. Error bars represent SD from six (A) or three (B-G) independent experiments. In B, C, F, G, dose-response curves for theoretical additive effects, calculated according to [22], are included for comparison (dotted line).

Back to article page